The share of biologic-based drugs in the global pharmaceutical market is on the rise.
Feb 2, 2013
By:
Patricia Van Arnum
The share of biologic-based drugs in the global pharmaceutical market is on the rise.
|
|
Researchers use inorganic catalysts as an alternative to biocatalysts in the selective conversion of sugars to produce chiral building blocks.
Feb 2, 2013
By:
Patricia Van Arnum
Researchers use inorganic catalysts as an alternative to biocatalysts in the selective conversion of sugars to produce chiral building blocks.
|
|
In the arena of pharmaceutical outsourcing, when speaking of partnerships, the discussion typically focuses on the relationship between a pharmaceutical/biopharmaceutical company as the sponsor company and a contract-service provider.
Feb 1, 2013
By:
Patricia Van Arnum
When speaking of partnerships, the discussion typically focuses on the relationship between a pharmaceutical/biopharmaceutical company as the sponsor company and a contract-service provider.
|
In the arena of pharmaceutical outsourcing, when speaking of partnerships, the discussion typically focuses on the relationship between a pharmaceutical/biopharmaceutical company as the sponsor company and a contract-service provider.
Feb 1, 2013
By:
Patricia Van Arnum
In the arena of pharmaceutical outsourcing, when speaking of partnerships, the discussion typically focuses on the relationship between a pharmaceutical/biopharmaceutical company as the sponsor company and a contract-service provider.
|
|
CROs are keeping pace with the increased globalization of the biopharmaceutical/pharmaceutical industry through a combination of acquisitions, partnerships, and select investments. The author examines these activities as well as the partnership strategies of CROs with academia to broaden their scope.
Feb 1, 2013
By:
Patricia Van Arnum
CROs are keeping pace with the increased globalization of the biopharmaceutical/pharmaceutical industry through a combination of acquisitions, partnerships, and select investments.
|
Financing from initial public offerings and global mergers and acquisitions were down in 2012 and venture-capital funding stayed strong.
Jan 9, 2013
By:
Patricia Van Arnum
Financing from initial public offerings and global mergers and acquisitions were down in 2012 and venture-capital funding stayed strong.
|
GlaxoSmithKline partners with the mobile telecommunications company Vodafone to tackle common infectious diseases in Africa.
Jan 9, 2013
By:
Patricia Van Arnum
GlaxoSmithKline partners with the mobile telecommunications company Vodafone to tackle common infectious diseases in Africa.
|
As a new year begins, what may be on the horizon for 2013 for the biopharmaceutical/pharmaceutical companies and their suppliers? A look ahead into what issues are shaping the industry.
Jan 9, 2013
By:
Patricia Van Arnum
As a new year begins, what may be on the horizon for 2013 for the biopharmaceutical/pharmaceutical companies and their suppliers? A look ahead into what issues are shaping the industry.
|
|
Process chemists employ a variety of approaches to improve yield, purity, and stereoselectivity.
Jan 2, 2013
By:
Patricia Van Arnum
Process chemists employ a variety of approaches to improve yield, purity, and stereoselectivity.
|
|
